VitaDX (France), is developing a non-invasive medical device for early detection of bladder cancer, based on a syndicate of French academic research. This simple urine sample analysis has attracted over €1.5M in preparation for clinical trials and a global market launch.
The technology operated by VitaDX is the result of a research collaboration between the Institute of Molecular Sciences of Orsay (ISMO) which is a CNRS at the University of South Paris, and the Kremlin-Bicêtre Hospital (also in Paris).
Conventional diagnostic tests for bladder cancer use cell microscopy from urine sample using a Papanicolaou stain – a technique which lacks sensitivity for early cancers (an average of just 20% sensitivity). This is because the cell’s morphology is not yet altered for a proper diagnosis to be possible.